Indoco Remedies Limited has informed the Exchange regarding a press release dated May 14, 2026, titled "Indoco Remedies successfully clears Malta Medicines Authority audit".
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indoco Remedies announced that its solid oral dosage form manufacturing facility (Unit I) at Baddi successfully cleared an inspection by the Malta Medicines Authority conducted from January 29 to February 3, 2026. The facility has received EU GMP certification, confirming compliance with European Good Manufacturing Practice requirements as per the EC Directive. This certification validates that the facility meets international quality standards. The company stated this reflects its commitment to quality and compliance with global regulatory standards. Indoco is a fully integrated pharmaceutical company with US$ 175 million turnover and 10 manufacturing facilities.
This EU GMP certification strengthens Indoco's international credibility and regulatory standing, potentially expanding its export opportunities to EU markets. However, it does not immediately impact revenue or orders.